Logo

Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in the US

Share this

Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in the US

Shots:

  • Alvotech will lead the development- registration- and supply of the biosimilars- while Teva will be exclusively commercializing the products in the US. Alvotech will receive upfront with subsequent milestone payments over the next several years
  • The companies will share the profit from the commercialization of the biosimilars. The collaboration leverages Teva’s commercial presence and extensive infrastructure in the US along with Alvotech’s experience and state-of-the-art biologics manufacturing
  • The collaboration will improve patient access for high-quality biosimilar medicines in the US

­ Ref: Teva | Image: PharmaShots

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions